Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.56 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1375802 | 1.00 | GAA (0.56) | GAAHSD17B10ALDH1A1SMN1; SMN2CYP1A2 | |
| Hydrochloric Acid SCHEMBL4152689 | 1.00 | GAA (0.56) | GAAHSD17B10ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL15150 | 0.97 | GAA (0.58) | GAAHSD17B10ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL9174370 | 0.97 | GAA (0.58) | GAAHSD17B10ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL10942934 | 0.97 | GAA (0.58) | GAAHSD17B10ALDH1A1SMN1; SMN2CYP1A2 | |
| Hydrochloric Acid SCHEMBL1375922 | 0.97 | HSD17B10 (0.56) | GAAHSD17B10ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL5499056 | 0.97 | GAA (0.58) | GAAHSD17B10ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL3862747 | 0.95 | GAA (0.56) | GAAHSD17B10ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL15571385 | 0.95 | GAA (0.56) | GAAHSD17B10ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL15571726 | 0.95 | GAA (0.56) | GAAHSD17B10ALDH1A1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1041306-C | Process for preparing a-cyanoacrylate | XINAN NORMAL UNIV (CN) | 1998-12-23 | — | — | CN | claimed |
| CN-1070636-A | The technology of preparation α-Qing Jibingxisuanzhi | XINAN NORMAL UNIV (CN) | 1993-04-07 | — | — | CN | claimed |
| WO-2025093590-A1 | HETEROARYL ESTER DERIVATIVES AS SODIUM CHANNEL INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-05-08 | — | — | WO | disclosed |
| CN-113563320-A | Compound containing thiophene structure and application thereof in medicine | 天津药物研究院有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-110467598-A | A kind of carbazole sulfonamide derivative prodrug or its officinal salt and its preparation method and application | INST MED BIOTECHNOLOGY CAMS | 2019-11-19 | — | — | CN | disclosed |
| CN-109956912-A | Carboxylic acid compound, preparation method and the medical usage of the oxadiazoles containing diphenyl | 中国医学科学院药物研究所 | 2019-07-02 | — | — | CN | disclosed |
| CN-104622809-B | The drug of modification for elaioplast nanometer particle | 英属哥伦比亚大学 | 2019-04-19 | — | — | CN | disclosed |
| EP-3415151-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | The University of British Columbia (CA) | 2018-12-19 | — | — | EP | disclosed |
| EP-2282724-B1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-09-05 | — | — | EP | disclosed |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-9968554-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-15 | — | — | US | disclosed |
| CN-1070636-A | The technology of preparation α-Qing Jibingxisuanzhi | XINAN NORMAL UNIV (CN) | 1993-04-07 | — | — | CN | disclosed |
| US-5104985-A | Rearrangement in the presence of an alkali metal bis (tris-lower alkyl silyl)amide | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1992-04-14 | — | — | US | disclosed |
| EP-0193132-B1 | LABDAN-DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-04-17 | — | — | EP | disclosed |
| US-4963537-A | REDUCE INTRAOCULAR PRESSURE | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-10-16 | — | — | US | disclosed |
| US-4851397-A | LOWERING INTRAOCULAR PRESSURE | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1989-07-25 | — | — | US | disclosed |
| US-4771049-A | REDUCING INTRAOCULAR PRESSURE | HOECHST-ROUSSEL PHARMACEUTICALS (US) | 1988-09-13 | — | — | US | disclosed |
| US-4677103-A | REDUCING INTRAOCULAR PRESSURE | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-06-30 | — | — | US | disclosed |
| US-4639443-A | INTRAOCULAR PRESSURE REDUCTION | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-01-27 | — | — | US | disclosed |
| EP-0193132-A2 | Labdan-derivatives, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1986-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | GAA 354/4885MAOB 1848/4885HSD17B10 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.